Annex to Regulations of central and regional group of quick response to AEFI/tuberculin diagnostics (subitem 1 of item 12)

PROTOCOL

of investigation and establishment of a causal association between serious and/or cluster of AEFI/tuberculin diagnostics and use of vaccine, tuberculin

Investigation and establishment of a causal association between serious and/or cluster of AEFI/tuberculin diagnostics and use of vaccine, tuberculin consists of 4 steps. **Step 1. Collection of information related to development of serious and/or cluster of AEFI after use of vaccine, tuberculin**

I. General information

Name of enterprise, institution, organization where immunization/tuberculin diagnostics took place______

Category of immunization or tuberculin diagnostics: mass campaign vaccination by age preschool school timmunization of travelers tuberculin diagnostics other (indicate)

Place of immunization/tuberculin diagnostics

Full name of person submitting protocol	Date of investigation// Date of filing protocol// This protocol is
Position	□ primary □ interim □ final
Place of work	
Office phone (with code)	
Mobile	
E-mail	

Information about person, in whom vaccine/tuberculin was used: Full name___

Sex \Box M \Box F

Date of birth (dd/mm/yyyy) ____/____ Address of person, in whom vaccine/tuberculin was used (city/village/settlement, street name, house number, phone number, etc.)

(for each case Trade name of vaccine(s)/ diluent or tuberculin, previously received	e of cluster of Date of vaccination/ tuberculin diagnostics	Time of	idual protocol Dose (first, second, etc.)	form shall be Batch number	filled in) Expiration date
				Vaccine or tuberculin Diluent Vaccine Diluent Vaccine Diluent Vaccine Diluent Vaccine Diluent	Vaccine or tuberculin Diluent Vaccine Diluent Vaccine Diluent Vaccine Diluent Vaccine Diluent
 left shoulde right shoulde shoulder (m) left hip right hip hip (not special optimized) left forearm right forearm forearm (me) Date of first/first 	der not specified) ecified) n rm	of AEFI (dd/m EFI (hours/mi	n) /	//	
Date of first v Status on date death invalidity recovering	visit to a health e of investigati	n facility becau ion of AEFI:		ld/mm/yyyy) _	//

\Box recovery with sequela
\Box without changes
🗆 unknown
If died, date and time of death shall be indicated (dd/mm/yyyy) _ // (hh/mm)
/
Autopsy done
□ yes (date) (dd/mm/yyyy) //
□ no
\Box planned on (date) (dd/mm/yyyy) / time (hh/mm) /
Comments on results of autopsy shall be attached
(if any)

II. Available information about person in whom vaccine/tuberculin were used prior to vaccination/tuberculin diagnostics

abeu prior to vacemation/tabercum a	0	T C
Criteria	Result	In case of positive response a comment shall be provided
Past history of similar AEFI regardless of vaccination/tuberculin diagnostics	Yes/No/Unknown	
Similar AEFI after previous vaccination/tuberculin diagnostics	Yes/No/Unknown	
Burdened history of allergy to vaccine/tuberculin, medicinal product or food, etc.	Yes/No/Unknown	
Burdened family history of allergy (availability of diseases which caused AEFI)	Yes/No/Unknown	
History of hospitalization in last 30 days with cause	Yes/No/Unknown	
Person in whom vaccine/tuberculin was used currently on concomitant medication	Yes/No/Unknown	
If yes, indicate trade name of medicinal product, indication, dose and date of start and end of treatment		
Whether any disease preceded the development of AEFI (30	Yes/No/Unknown	
days)/availability of genetic disorders		
For adult women in whom vaccine was u	sed it is necessary to i	indicate:
Currently pregnant		
Yes (weeks)	/No/Unknown	
Currently breastfeeding		

Yes/No/Unknown

For infants under 1 year in whom vaccine was used, indicate: Delivery procedure was:

 \Box full term \Box preterm \Box in term after 42 weeks of gestation

 \Box physiological \Box caesarean section \Box with complications (specify)

Birth weight ______ g Newborn state according to Apgar scale ______ III. Details related to case of serious and/or cluster of AEFI after use of vaccine, tuberculin Source of information (that applied)

- □ medical examination
- \Box autopsy results
- □ documents (indicate)

Full name of person, who first examined/treated the person in whom immunization/tuberculin diagnostics were conducted

Full name of other person, who consulted and gave medical care to person in whom immunization/tuberculin diagnostics were conducted

Other sources of information

Signs of AEFI in chronological order from the time of immunization/tuberculin diagnostics

Full name of person who gave details about AEFI

Date (dd/mm/yyyy) ____/__/____ Time (hours/min) __/___

Position

Place of work

Office telephone (with code)

Mobile

E-mail

Documents containing documented confirmation of patient's status (tick the necessary):

 \Box case sheet

- □ discharge summary
- □ consultation of main specialists
- \Box laboratory reports
- □ results of instrumental studies
- \Box autopsy report:
 - □ histological investigation
 - □ virological investigation
 - □ bacteriological investigation
 - □ toxicological investigation

Provisional/final diagnosis

IV. Details of vaccine/tuberculin in case of serious and/or cluster of AEFI

Number of persons in whom immunization and/or tuberculin diagnostics was conducted at enterprise, in institution, organization, tuberculin tests oblast/city/district. Attach record, if available

Trade name of vaccine/tuberculin Number of doses/

^{1.} Vaccine/tuberculin dose number in person, in whom were registered serious and/or cluster of AEFI

When vaccine is used from multidose vials, indicate the patient in series in whom vaccination was made \Box

If tuberculin is used indicate the patient in series in whom tuberculin diagnostics was made \Box

2. Was there an error in using vaccine,	Yes*/No
tuberculin because of non-adherence to	
information for their use (e.g.	
immunization and/or tuberculin	
diagnostics after vaccine, tuberculin	
expired, non-adherence to	
contraindications, etc.)	
3. Whether vaccine/tuberculin	Yes*/No/Unable to assess
administered could have been unsterile	
4. Whether physical condition of	Yes*/No/Unable to assess
vaccine, tuberculin (colour, turbidity,	
foreign substances, etc.) was abnormal	
at the time of their administration	
5. Whether an error was made by person	Yes*/No/Unable to assess
conducting immunization/tuberculin	
diagnostics in:	
1) dilution/preparation of vaccine	
(wrong medicinal product or wrong	
diluent was used, improper mixing,	
improper syringe filling, etc.);	
2) use of tuberculin (wrong medicinal	
product used, improper syringe filling	
etc.)	
6. Was the vaccine, tuberculin	Yes*/No/Unable to assess
administered/used incorrectly (wrong	
dose or route of administration, wrong	
site of administration, wrong needle size	
etc.)	
7. Number immunized from the concerned	d vial/ampoule with vaccine o
4 - 4 - 4 4 + 4 - 4 - 4 - 4 - 4 1 1	41

7. Number immunized from the concerned vial/ampoule with vaccine or number tested with the tuberculin diagnostics from the concerned vial/ampoule at particular enterprise, institution, organization where immunization/tuberculin diagnostics conducted

8. Number immunized with the concerned vaccine or number tested with concerned tuberculin while tuberculin diagnostics at particular enterprise, institution, organization on the same day

9. Number immunized with the concerned vaccine batch and number tested with concerned tuberculin batch while tuberculin diagnostics at particular enterprise, institution, organization on the same day.

10. Is this case a part of a cluster? Yes/No

If yes, indicate how many other cases have been detected in the cluster? 11. Did all the cases in the cluster Yes/No receive vaccine/tuberculin diagnostics from the same vial/ampoule of vaccine/tuberculin If no, indicate batch and number of vials/ampoules used in the cluster at conducting immunization/tuberculin diagnostics * Enter details.

V. Information about enterprise, institution, organization where immunization/tuberculin diagnostics conducted

Syringes and needles used Are AD syringes used for immunization/tuberculin diagnostics (to avoid repeated use) If no, specify the type of syringes used: □ Disposable □ Other

Specific key findings/additional observations and comments shall be indicated

Reconstitution: (complete only if diluent is applicable)

Reconstitution procedure	
Same syringe used for vials of same	Yes/No/NA
vaccine	
Same syringe used for reconstituting	Yes/No/NA
different vaccines	
Separate reconstitution syringe for each	Yes/No/NA
vaccine vial	
Separate reconstitution syringe for each	Yes/No/NA
vaccination	
Are the vaccines and diluents used the	Yes/No/NA
same as those recommended by the	
manufacturer	

Specific key findings/additional observations and comments

VI. Cold chain at storage and transport of vaccine/tuberculin

Vaccine/tuberculin storage in vaccination room Is the temperature of the Yes/No

vaccine/tuberculin storage refrigerator		
monitored		
If "yes", was there any deviation outside	Yes/No	
of 2-8° C after the vaccine/tuberculin		
was placed in refrigerator		
If "yes", provide details of temperature monitoring		

Was the separate refrigerator for storing vaccines/tuberculin, diluents, syringes,	Yes / No / Unkn
needles used	
Was any other item other than	Yes / No / Unkn
vaccines/tuberculin, diluents, syringes,	
needles in the refrigerator (or freezer)	
Were any partially used reconstituted	Yes / No / Unkn
vaccines in the refrigerator	
Were any vaccines/tuberculin (expired, no label, frozen, with VVM of changed colour, etc.) in the refrigerator	Yes / No / Unkn
Were any diluents (expired, manufacturer/applicant not matched, microcracked, dirty vials/ampoules) in the refrigerator	Yes / No / Unkn
Specific key findings/additional observation	ons and comments

Type of carrier used to transport vaccine/tuberculin to vaccination room

Was the vaccine/tuberculin carrier sent	Yes / No / Unkn
on the same day as vaccination/	
tuberculin diagnostics	

Was a conditioned ice-pack used Yes / No / Unkn

Specific key findings/additional observations and comments

Were any similar clinical manifestations Yes / No / Unkn

reported within a time period similar to when AEFI occurred in the same locality If yes, indicate the background morbidity level by oblast/city, where AEFI was registered ______

VIII. Other findings/observations/comments

Step 2. Collection of information for establishing causal association between serious and/or cluster of AEFI and use of vaccine, tuberculin

I. Is there strong evidence for other causes Does clinical Yes*/No/Unknown/NA Remarks examination, or laboratory tests on the patient, in whom vaccine, tuberculin were used, confirm another cause of serious and/or cluster of AEFI

II. Is there a known causal association between the development of AEFI and use of the vaccine/tuberculin or vaccination/tuberculin diagnostics *Vaccine, tuberculin-related reaction (underline the appropriate)* Yes*/No/Unknown/NA 1. Is there evidence in the Remarks medical and scientific literature that this vaccine/ tuberculin may cause the reported AEFI even if administered according to instruction for medical use Yes*/No/Unknown/NA 2. Did a specific Remarks laboratory test(s) demonstrate the causal

association between this AEFI and vaccine/tuberculin used Immunization/ tuberculin diagnostics program error-related reaction Yes*/No/Unknown/NA 3. Was an error made by Remarks person conducting immunization/ tuberculin diagnostics at administration of vaccine/tuberculin because of non-adherence to recommendations for their use (e.g. immunization and/or tuberculin diagnostics beyond the expiry date of vaccine/tuberculin, nonadherence to contraindications etc.) (indicate whether vaccine, tuberculin were used in accordance with instruction for medical use in part of indications, contraindications, doses, regimen, storage conditions, etc. Vaccines from different manufacturers but of one type may have different specifications for medical use and failure to comply with them can result in AEFI) 4. Was the Yes*/No/Unknown/NA Remarks vaccine/tuberculin administered unsterile (indicate information related to availability or lack of signs specific to toxic shock syndrome (vomiting, diarrhoea, cyanosis and high temperature), and terms of their development (within a few hours), as well as local tenderness and tissue infiltration) Yes*/No/Unknown/NA Remarks 5. Was the vaccine's/ tuberculin physical condition (e.g. colour, turbidity, presence of foreign substances etc.) abnormal at the time of administration (indicate information related to availability or lack of abnormal colour (turbidity or presence of foreign substances, which may confirm that the vaccine contents


are abnormal and may have caused the AEFI)

Yes*/No/Unknown/NA Remarks 6. Was an error made by person conducting immunization/ tuberculin diagnostics in: 1) vaccine constitution/preparation (e.g. wrong medicinal product, wrong diluent, improper mixing, improper syringe filling, wrong dose, etc.); 2) tuberculin use (e.g. wrong medicinal product, improper syringe filling, wrong dose, etc.); Yes*/No/Unknown/NA Remarks 7. Was an error made by person in charge at transport, storage of vaccine/tuberculin (a break in the cold chain) Yes*/No/Unknown/NA Remarks 8. Was an error made by person conducting immunization/ tuberculin diagnostics at administration/use of vaccine/tuberculin (wrong dose or route of administration, wrong site of administration; wrong needle size etc.) (indicate whether the age-specific dose, site and route of administration comply with instruction for medical use of specific vaccine) Immunization/tuberculin diagnostics anxiety-related reaction 9. Could the AEFI have Yes*/No/Unknown/NA Remarks been caused by anxiety about the immunization/tuberculin diagnostics (vasovagal, hyperventilation or stressrelated disorder, etc.) (indicate the child's age (adolescent specific event), place of immunization (preschool institution, school))

III. AEFI time window taking in account type of vaccine/tuberculin used Yes*/No/Unknown/NA Did the AEFI occur Remarks within an appropriate time window after this vaccine/ tuberculin administration IV. Strong evidence against a causal association Yes*/No/Unknown/NA Remarks Is there strong evidence against a causal association If yes, provide a justification V. Other factors for differentiation between the development of AEFI and use of vaccine/tuberculin 1. Could the AEFI occur Yes*/No/Unknown/NA Remarks independently of vaccination/tuberculin diagnostics (background rate of morbidity in Autonomous Republic of Crimea/oblast/Kyiv, Sevastopol, where AEFI has been registered) (indicate the background rate of somatic and infectious diseases for different age-groups of population of administrative territorial unit which gives the ability to compare incidence of development of AEFI among vaccinated and nonvaccinated of one age-group who live in one administrative territorial unit) 2. Could the AEFI be a Yes*/No/Unknown/NA Remarks manifestation of another health condition 3. Did a comparable AEFI Yes*/No/Unknown/NA Remarks occur after a previous dose of a similar vaccine/tuberculin (indicate the history of previous vaccination to be analyzed in detail) Remarks Yes*/No/Unknown/NA 4. Was there exposure to a potential risk factor or toxin prior to the AEFI (indicate whether a surgical procedure or chemotherapy were conducted or medicinal products used prior to vaccination) Yes*/No/Unknown/NA 5. Was there acute illness Remarks prior to the AEFI

(indicate whether any disease occur		
prior to vaccination, AEFI may be		
the cause of this disease in post-		
vaccination period) 6. Did the event occur in	Yes*/No/Unknown/NA	Remarks
	1 es //10/ Ulikilowii/10A	Kemarks
the past independently of		
vaccination/tuberculin		
diagnostics (indicate whether a		
similar AEFI occurred in the		
vaccinee and family in the past		
independently of immunization)		D 1
7. Was the patient in	Yes*/No/Unknown/NA	Remarks
whom		
immunization/tuberculin		
diagnostics were		
conducted taking any		
medicinal product prior to		
vaccination/ tuberculin		
diagnostics		
(indicate whether vaccinee took any		
medicinal product in day of		
vaccination since AEFI may be the		
result of use of medicinal product as well as vaccine)		
· · · · · · · · ·	Yes*/No/Unknown/NA	Remarks
8. Is there a biological	1 es ·/INO/UIIKIIOWII/INA	Kemarks
plausibility that the		
vaccine could cause the		
AEFI		
(indicate whether AEFI are similar to the	ne	
natural course of the infection		
including the results of laboratory, instr studies as additional qualifying factor)	umentai	
*In case of positive response give	clarification in "Note" column	

Step 3. Algorithm of determination of causal association between serious and cluster of AEFI and use of vaccine and tuberculin



Step 4. Categories of causal association between serious and/or cluster of AEFI and use of vaccine, tuberculin according to step 3 algorithm of determination

Adequate information available	 □A. Consistent casual association between AEFI and use of vaccine/tuberculin □A1. Vaccine, tuberculin properties-related reaction □A2. Vaccine, tuberculin manufacturing failures-related reaction □A3. Programme error-related reaction □A4. Immunization, tuberculin diagnostics anxiety-related reaction 	 B. Inconsistent causal association between AEFI and use of vaccine/tuberculin □ B1. Temporary relationship is consistent but there is insufficient definitive evidence for vaccine, tuberculin causal association (may be new vaccine, tuberculin linked event) □ B2. Other factors do not allow to differentiate between AEFI and use of vaccine, tuberculin 	C. Inconsistent causal association between AEFI and use of vaccine/tuberculin □ C1. Causal event
Adequate information not available	vaccine, tuberculin Indicate the reasons why	sal association between A y classification of causal a itional information requir	association is

Summarize the classification of causal association between serious and/or cluster of AEFI and use of vaccine, tuberculin logic:______.

With available evidence regional/central group of quick response could conclude that	at
(underline the appropriate)	

the classification of causal association is_____

because:_____

Head of Group_____

(full name)

(date)